Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.
作者信息
Rosman Yossi, Lavi Noa, Meir-Shafrir Keren, Lachover-Roth Idit, Cohen-Engler Anat, Mekori Yoseph A, Confino-Cohen Ronit
机构信息
Allergy and Clinical Immunology Unit, Meir General Hospital, Kfar-Saba, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Hematology Division, Rambam Medical Center, Haifa, Israel.
出版信息
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3487-3489. doi: 10.1016/j.jaip.2021.06.032. Epub 2021 Jul 2.
Abstract
摘要
相似文献
1
Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.BNT162b2 mRNA新冠疫苗在肥大细胞疾病患者中的安全性
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3487-3489. doi: 10.1016/j.jaip.2021.06.032. Epub 2021 Jul 2.
2
The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.全国性 BNT162b2 mRNA COVID-19 疫苗接种计划的初步影响。
Int J Infect Dis. 2021 Jul;108:116-118. doi: 10.1016/j.ijid.2021.05.021. Epub 2021 May 13.
3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA新冠疫苗的安全性和有效性
N Engl J Med. 2021 Apr 22;384(16):1576-1577. doi: 10.1056/NEJMc2036242. Epub 2021 Feb 17.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.BNT162b2 mRNA新冠疫苗的安全性与有效性。回复
N Engl J Med. 2021 Apr 22;384(16):1578. doi: 10.1056/NEJMc2036242. Epub 2021 Feb 17.
5
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.BNT162b2（辉瑞/生物科技）疫苗在第 2 剂接种后 ≥7 天对 COVID-19 的有效率为 95%。
Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2.
6
Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.透析患者接种新型冠状病毒2型BNT162b2 mRNA疫苗的经验
Kidney Int. 2021 Jun;99(6):1496-1498. doi: 10.1016/j.kint.2021.04.006. Epub 2021 Apr 20.
7
Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.BNT162b2（辉瑞-生物科技公司）和mRNA-1273（莫德纳公司）SARS-CoV-2 mRNA疫苗在透析患者中的免疫原性比较。
Kidney Int. 2021 Sep;100(3):697-698. doi: 10.1016/j.kint.2021.07.004. Epub 2021 Jul 13.
8
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2信使核糖核酸新冠疫苗在全国大规模疫苗接种中的应用情况
N Engl J Med. 2021 May 20;384(20):1968-1970. doi: 10.1056/NEJMc2104281. Epub 2021 Apr 21.
9
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.BNT162b2信使核糖核酸新冠疫苗在全国大规模疫苗接种中的应用。回复
N Engl J Med. 2021 May 20;384(20):1970. doi: 10.1056/NEJMc2104281. Epub 2021 Apr 21.
10
Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.BNT162b2 mRNA新冠疫苗接种后出现冻疮样病变：一例病例报告提示“新冠脚趾”是由对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的免疫反应所致
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e630-e632. doi: 10.1111/jdv.17451. Epub 2021 Jun 30.
引用本文的文献
1
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy.COVID-19疫苗在肥大细胞疾病中的安全性和耐受性：来自意大利单一中心的真实数据
Vaccines (Basel). 2024 Feb 16;12(2):202. doi: 10.3390/vaccines12020202.
2
COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated.在肥大细胞增多症患者中接种新冠病毒疫苗——辉瑞-BioNTech信使核糖核酸疫苗是安全的，且耐受性良好。
J Allergy Clin Immunol Pract. 2022 May;10(5):1377-1379. doi: 10.1016/j.jaip.2022.01.037. Epub 2022 Feb 3.
3
Safety of COVID-19 vaccination in patients with clonal mast cell disorders.克隆性肥大细胞疾病患者接种新型冠状病毒肺炎疫苗的安全性
J Allergy Clin Immunol Pract. 2022 May;10(5):1374-1376.e3. doi: 10.1016/j.jaip.2022.01.030. Epub 2022 Feb 1.
4
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges.依靠新冠疫苗：洞察当前策略、进展与未来挑战
Biomedicines. 2021 Nov 22;9(11):1740. doi: 10.3390/biomedicines9111740.
5
Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.新型冠状病毒2疫苗在真实世界研究中的有效性和安全性：一项系统评价与荟萃分析
Infect Dis Poverty. 2021 Nov 14;10(1):132. doi: 10.1186/s40249-021-00915-3.
Zotero 插件